SAMSUNG-BIOEPIS
Samsung Bioepis Co., Ltd. today announced real-world data of BENEPALI™ in patients with moderate to severe psoriasis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). The results will be presented at the 2019 European Academy of Dermatology and Venereology (EADV) Congress in Madrid, Spain.1
BADBIR is a UK and Ireland observational study that assesses the long-term safety of biologic treatments for psoriasis, in which Samsung Bioepis participated since May 2016. The study included BADBIR-registered patients treated with BENEPALI™ from January 01, 2016 to September 01, 2018. Among 269 patients who received BENEPALI™, clinical data of 189 patients were available, and were included in the analysis.
At baseline enrollment, the mean disease duration was 22.6 years and the mean Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores were 11.6 and 13.1, respectively. The median treatment period was 14.1 months and the discontinuation rate was 26.3%. Of the 48 patients who had their PASI score available both at baseline and at six months, disease activity of 20 patients with baseline PASI < 10 (mean PASI 3.2) did not increase after six months (mean PASI 3.2). Disease activity of 28 patients with baseline PASI ≥ 10 (mean PASI 15.7) was reduced after six months (mean PASI 5.0).
“Results from this study show that BENEPALI was effective when used by patients in the real-life setting,” said Seongwon Han, MD, Vice President and Lead of Medical Team, Samsung Bioepis. “We hope the growing wealth of real-world data on BENEPALI will help physicians make informed decisions when treating patients with biosimilars.”
The results will be presented during an Oral Free Communication session scheduled at 15:40-15:50 on October 10, 2019 in N109-110. Samsung Bioepis and Biogen are also jointly hosting an Industry Hub Session titled “Shedding new light on the role of anti-TNFs in psoriasis” which will take place between 14:00-14:45 on October 10, 2019 in Room A9.1, IFEMA Ferida de Madrid, Spain. Topics include “Anti-TNFs in psoriasis: Will the use of more affordable options enhance current treatment algorithms?” and “Anti-TNF biosimilars: Real world insights and data.”
Samsung Bioepis and Biogen were the first to launch biosimilars of the three most prescribed anti-TNF therapies for immunological diseases across Europe: etanercept, infliximab and adalimumab.
About BENEPALITM (etanercept)
BENEPALI™ (etanercept), a biosimilar referencing ENBREL®2 , was approved by the European Commission (EC) in January 2016 for the treatment of adults with moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis), and plaque psoriasis. BENEPALI™ is currently available in 25 countries in Europe and is the most prescribed etanercept across France, Germany, Italy, Spain, and the United Kingdom combined.3
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com .
1. Egeberg et al., Real World Data of SB4 (Etanercept Biosimilar) in Patients with Psoriasis from the British Association of Dermatologists Biologic Interventions Register (BADBIR). EADV 2019, Madrid, Spain
2. ENBREL®
is a registered trademark of Amgen/Pfizer.
3. Data on File: IQVIA, GERS, Insight Health ODV
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005493/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press release
Five-year contract to drive innovation in stimulation, intervention, digital and frac automationAgreement underscores gas as a pivotal fuel for global energy demand and a bridge to lower-carbon systems Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconve
Tabelog, Japan's Largest (*1)Restaurant Search and Reservation Service,Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press release
Experience Japan's Authentic Culinary Scene in Your Language — From Search to Reservation, All on Your SmartphoneRanked No. 1 in Downloads Among "Japanese Gourmet Search Apps" Chosen by International Travelers (*2) Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photo
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
I-care Becomes a Unicorn23.12.2025 10:45:00 CET | Press release
The Belgian company has surpassed the billion-euro valuation mark following a €20 million fundraising and refinancing round. I-care announces the completion of a €20 million fundraising and refinancing operation, carried out as a round reserved for existing shareholders and employees. Based on this operation, the group's valuation reaches €1 billion, making I-care a unicorn. "Becoming a unicorn is a symbolic milestone. To achieve this, we chose to invest before reaping the rewards: we bet on AI when few believed in it, we prioritized R&D, and we built our own production unit. These choices were sometimes difficult, but they were essential to staying ahead of the game. Today, our results confirm that this strategy was the right one," explains Fabrice Brion, CEO of I-care. This fundraising round is the first step in a three-phase development plan. Following the “Eau Rouge” operation in 2022, which enabled I-care to become the world leader in predictive maintenance, the company has now se
Liquid Reply Joins the Agentic AI Foundation (AAIF) to Advance Open, Trusted Agentic AI23.12.2025 10:00:00 CET | Press release
Liquid Reply, specialising in platform engineering and cloud-native technologies within the Reply Group, today announced that it has joined the Agentic AI Foundation (AAIF). The newly established foundation was launched under the auspices of the Linux Foundation and provides a neutral, open governance framework for the development of agent-based AI systems. Members collaborate transparently to develop tools, protocols, and specifications that remain available as open-source resources for the global community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223604862/en/ Through its membership, Liquid Reply will engage the AAIF community and actively support the establishment of open standards for the next generation of AI-powered applications. By joining the AAIF, Liquid Reply reinforces its commitment to open-source and community-driven innovation, and supports the creation of shared technical foundations for the responsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom